Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study

The Lancet HIV

Volumn 2, Issue 12, 2015, Pages e520-e529

  Elliott, Julian H ^a   McMahon, James H ^a   Chang, Christina C ^a,b   Lee, Sulggi A ^c   Hartogensis, Wendy ^c   Bumpus, Namandje ^d   Savic, Rada ^c   Roney, Janine ^a   Hoh, Rebecca ^c   Solomon, Ajantha ^b   Piatak, Michael ^e   Gorelick, Robert J ^e   Lifson, Jeff ^e   Bacchetti, Peter ^c   Deeks, Steven G ^c   Lewin, Sharon R ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR PLUS RITONAVIR; CREATININE; DARUNAVIR PLUS RITONAVIR; DISULFIRAM; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS RALTEGRAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ANTIRETROVIRUS AGENT;

ABDOMINAL PAIN; ADULT; AGED; ALCOHOLISM; ANTIRETROVIRAL THERAPY; ANXIETY DISORDER; APHTHOUS STOMATITIS; ARTICLE; BEHAVIOR DISORDER; BLURRED VISION; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONSTIPATION; COORDINATION DISORDER; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HEART PALPITATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCEMIA; HYPERNATREMIA; HYPERTENSION; HYPOKALEMIA; HYPOPHOSPHATEMIA; LATENT VIRUS INFECTION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MEMORY DISORDER; MIDDLE AGED; MYALGIA; NAUSEA; OLFACTORY NERVE DISEASE; PHARMACOKINETIC ASSAY; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; REVERSAL REACTION; SHORT COURSE THERAPY; SLEEP DISORDER; SORE THROAT; THROAT IRRITATION; THROMBOCYTOPENIA; VIRUS LATENCY; VIRUS TRANSCRIPTION; XEROSTOMIA; AUSTRALIA; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; EPIDEMIOLOGY; GENETIC TRANSCRIPTION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MULTICENTER STUDY; PHYSIOLOGY; TREATMENT OUTCOME; UNITED STATES; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; AUSTRALIA; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DISULFIRAM; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD; VIRUS LATENCY;

EID: 84977937246     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(15)00226-X     Document Type: Article

References (31)

1. Palella, FJ, Delaney, KM, Moorman, AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338 (1998), 853–860.
2. Perelson, AS, Essunger, P, Cao, Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387 (1997), 188–191.
3. Finzi, D, Hermankova, M, Pierson, T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278 (1997), 1295–1300.
4. Maartens, G, Celum, C, Lewin, SR, HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 384 (2014), 258–271.
5. Deeks, SG, HIV: shock and kill. Nature 487 (2012), 439–440.
6. Archin, NM, Liberty, AL, Kashuba, AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487 (2012), 482–485.
7. Elliott, JH, Wightman, F, Solomon, A, et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog, 10, 2014, e1004473.
8. Rasmussen, TA, Tolstrup, M, Brinkmann, CR, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1 (2014), e13–e21.
9. Williams, E, Effects of alcohol on workers with carbon disulfide. J Am Med Assoc, 109, 1937, 1472.
10. Xing, S, Bullen, CK, Shroff, NS, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 85 (2011), 6060–6064.
11. Yang, HC, Xing, S, Shan, L, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 119 (2009), 3473–3486.
12. Doyon, G, Zerbato, J, Mellors, JW, Sluis-Cremer, N, Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog (PTEN). AIDS 27 (2013), F7–11.
13. Spivak, AM, Andrade, A, Eisele, E, et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 58 (2014), 883–890.
14. Somsouk, M, Dunham, RM, Cohen, M, et al. The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PLoS One, 9, 2014, e116306.
15. US Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, version 2.0. http://rsc.tech-res.com/Document/safetyandpharmacovigilance/DAIDS_AE_GRADING_TABLE_v2_NOV2014.pdf, November, 2014 (accessed Nov 4, 2015).
16. Talbott, GD, Gander, O, Antabuse, 1973. Md State Med J 22 (1973), 60–63.
17. Faiman, M, Jensen, J, Elimination kinetics of disulfiram in alcoholics after single and repeated doses. Clin Pharmacol Ther 36 (1984), 520–526.
18. Christensen, JK, Ronsted, P, Vaag, UH, Side effects after disulfiram. Comparison of disulfiram and placebo in a double-blind multicentre study. Acta Psychiatr Scand 69 (1984), 265–273.
19. Enghusen Poulsen, H, Loft, S, Andersen, JR, Andersen, M, Disulfiram therapy—adverse drug reactions and interactions. Acta Psychiatr Scand Suppl 369 (1992), 59–65.
20. Doi, M, Hirayama, J, Sassone-Corsi, P, Circadian regulator CLOCK is a histone acetyltransferase. Cell 125 (2006), 497–508.
21. Van Lint, C, Emiliani, S, Ott, M, Verdin, E, Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15 (1996), 1112–1120.
22. Shehu-Xhilaga, M, Rhodes, D, Wightman, F, et al. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells. AIDS 23 (2009), 2047–2050.
23. Konig, R, Zhou, Y, Elleder, D, et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135 (2008), 49–60.
24. Zeichner, SL, Mueller, BU, Pizzo, PA, Dimitrov, DS, Kinetics of HIV-1 RNA concentration changes in pediatric patients. Pathobiology 64 (1996), 289–294.
25. Ackermann, K, Revell, VL, Lao, O, Rombouts, EJ, Skene, DJ, Kayser, M, Diurnal rhythms in blood cell populations and the effect of acute sleep deprivation in healthy young men. Sleep 35 (2012), 933–940.
26. Wightman, F, Solomon, A, Khoury, G, et al. Both CD31(+) and CD31(-) naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis 202 (2010), 1738–1748.
27. Markham, PD, Salahuddin, SZ, Veren, K, Orndorff, S, Gallo, RC, Hydrocortisone and some other hormones enhance the expression of HTLV-III. Int J Cancer 37 (1986), 67–72.
28. Cole, SW, Korin, YD, Fahey, JL, Zack, JA, Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production. J Immunol 161 (1998), 610–616.
29. Jones, RB, O'Connor, R, Mueller, S, et al. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog, 10, 2014, e1004287.
30. Laird, GM, Bullen, CK, Rosenbloom, DI, et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 125 (2015), 1901–1912.
31. Mothe, B, Climent, N, Plana, M, et al. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. J Antimicrob Chemother 70 (2015), 1833–1842.